



2025-2026 General Assembly

SENATE BILL 257: 2026 Appropriations Act, Sec. 9G.5: Funds for Additional Opioid Remediation Activities

Analysis of: S.L. 2026-41, Sec. 9G.5

Date: August 14, 2026
Prepared by: Legislative Analysis
Division Staff

Section 9G.5 of S.L. 2026-41 (Senate Bill 257) directs the use of \$6 million from the funds appropriated to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) of the Department of Health and Human Services from the Opioid Abatement Fund. The \$6 million is for the 2026-2027 fiscal year and is nonrecurring, and must be allocated as follows:

- \$4 million to the Local Management Entities/Managed Care Organizations, to be spread equally among them and used to support opioid remediation activities in certain counties.
- \$1 million for the purchase of intranasal opioid antagonists for distribution within North Carolina.
- \$1 million to fund a contract for the purchase of intranasal and intramuscular opioid antagonists for distribution in North Carolina, and related ancillary services, as provided for in Section 9G.6 of this act.

The recipients of these directed grants are required to report to DMH/DD/SUS, the Joint Legislative Oversight Committee on Health and Human Services, and the Fiscal Research Division on the use of these grants. The reports must be submitted by September 1, 2028.

This section became effective July 1, 2026.

Kara McCraw
Director



* S 2 5 7 - S M D C - 8 1 S L - V - 5 *

Legislative Analysis
Division
919-733-2578